Other
PSMA PET
PSMA PET is an intervention with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DIAGNOSTIC TEST
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_2
1
25%
Ph not_applicable
3
75%
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Other(1)
Detailed Status
Recruiting3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 21 (25.0%)
N/A3 (75.0%)
Trials by Status
recruiting375%
unknown125%
Recent Activity
3 active trials
Showing 4 of 4
recruitingnot_applicable
68Ga-PSMA PET in the Renal Cell Carcinoma
NCT04987086
recruitingphase_2
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
NCT03495427
recruitingnot_applicable
The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA)
NCT06867588
unknownnot_applicable
68Ga-PSMA PET in the Prostate Cancer
NCT04967001
Clinical Trials (4)
Showing 4 of 4 trials
NCT04987086Not Applicable
68Ga-PSMA PET in the Renal Cell Carcinoma
NCT03495427Phase 2
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
NCT06867588Not Applicable
The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA)
NCT04967001Not Applicable
68Ga-PSMA PET in the Prostate Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DIAGNOSTIC TEST
- Total Trials
- 4